Boehringer Taps Gubra For Early-Stage Obesity Deal

11 Sep 2017

• By Lubna Ahmed

Boehringer Ingelheim has signed a collaboration with Denmark-based Gubra focusing on the development of peptides to treat obesity, with Gubra to receive up to €250m in upfront and potential milestone payments.

Puzzle — Boehringer adds obesity piece to diabetes offering

Adding to its already busy metabolic disease portfolio, Boehringer Ingelheim GMBH has sealed a collaboration and license agreement with Denmark-based Gubra ApS, to develop peptide compounds for obesity. Gubra stands to receive up to €250m in upfront and success-based development and commercialization milestone payments, although details of the split between upfront payments and milestones were not disclosed.

Boehringer has various candidates in late preclinical and early clinical stages that it believes address the high therapeutic need in obesity, which a spokesperson described as

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

12 May 2025

• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

12 May 2025

• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pharma Left Hanging After US/UK Trade Pact

09 May 2025

• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

08 May 2025

• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Quick Listen: Scrip’s Five Must-Know Things

12 May 2025

• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.